Impact of cilostazol on intimal proliferation after directional coronary atherectomy.

No abstract is available for this paper.

• Publication year

  1998

• Venue

  American Heart Journal

• Publication date

  1998-03-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/S0002-8703(98)70327-8PMID 9506336
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Arterial remodeling after coronary angioplasty: a serial intravascular ultrasound study.

  1996cited by this paper
• Patterns and mechanisms of in-stent restenosis. A serial intravascular ultrasound study.

  1996cited by this paper
• Effect of cilostazol on the production of platelet-derived growth factor in cultured human vascular endothelial cells.

  1996cited by this paper
• Pharmacologic Treatment of Intimal Hyperplasia After Metallic Stent Placement in the Peripheral Arteries: An Experimental Study

  1995cited by this paper
• Quantitative assessment with intracoronary ultrasound of the mechanisms of restenosis after percutaneous transluminal coronary angioplasty and directional coronary atherectomy.

  1995cited by this paper
• Synergistic interactions between selective pharmacological inhibitors of phosphodiesterase isozyme families PDE III and PDE IV to attenuate proliferation of rat vascular smooth muscle cells.

  1994cited by this paper
• A comparison of balloon-expandable-stent implantation with balloon angioplasty in patients with coronary artery disease. Benestent Study Group.

  1994cited by this paper
• A randomized comparison of coronary-stent placement and balloon angioplasty in the treatment of coronary artery disease. Stent Restenosis Study Investigators.

  1994cited by this paper
• Intimal hyperplasia, vascular modeling, and the restenosis problem.

  1994cited by this paper
• Two major signal pathways linked.

  1993cited by this paper
• Inhibition of the EGF-activated MAP kinase signaling pathway by adenosine 3',5'-monophosphate.

  1993cited by this paper
• The pathogenesis of atherosclerosis: a perspective for the 1990s

  1993cited by this paper
• Cilostazol, a novel cyclic AMP phosphodiesterase inhibitor, prevents reocclusion after coronary arterial thrombolysis with recombinant tissue-type plasminogen activator.

  1993cited by this paper
• Arterial injury and the enigma of coronary restenosis.

  1992cited by this paper
• Inhibition of pig aortic smooth muscle cell DNA synthesis by selective type III and type IV cyclic AMP phosphodiesterase inhibitors.

  1992cited by this paper
• Effect of Cilostazol, a Cyclic AMP Phosphodiesterase Inhibitor, on the Proliferation of Rat Aortic Smooth Muscle Cells in Culture

  1992cited by this paper
• Inhibition of neointimal smooth muscle accumulation after angioplasty by an antibody to PDGF

  1991cited by this paper
• Restenosis after coronary angioplasty: an overview.

  1991cited by this paper
• Clinical trials of restenosis after coronary angioplasty.

  1991cited by this paper
• PLATELET-DERIVED GROWTH FACTOR

  1989cited by this paper
• Restenosis After Coronary Angioplasty: Potential Biologic Determinants and Role of Intimal Hyperplasia

  1989cited by this paper
• Platelet-derived growth factor.

  1989cited by this paper
• Incidence of restenosis after successful coronary angioplasty: a time-related phenomenon. A quantitative angiographic study in 342 consecutive patients at 1, 2, 3, and 4 months.

  1988cited by this paper
• Aspirin and dipyridamole in the prevention of restenosis after percutaneous transluminal coronary angioplasty.

  1988cited by this paper
• Percutaneous transluminal coronary angioplasty in 1985-1986 and 1977-1981. The National Heart, Lung, and Blood Institute Registry.

  1988cited by this paper
• Comparison of the inhibitory effects of cilostazol, acetylsalicylic acid and ticlopidine on platelet functions ex vivo. Randomized, double-blind cross-over study.

  1987cited by this paper
• Effect of cilostazol on platelet aggregation and experimental thrombosis.

  1985cited by this paper
• Purification of cyclic adenosine monophosphate phosphodiesterase from human platelets using new-inhibitor Sepharose chromatography.

  1984cited by this paper
• Purification of cyclic adenosine monophosphate phosphodiesterase from human platelets using new-inhibitor sepharose chromatography

  1984cited by this paper

• A Critical Review of the Molecular and Clinical Effects of Cilostazol After Percutaneous Coronary Intervention

  2026cites this paper
• The effect of cilostazol on the platelet-derived growth factor-beta/beta isoform reduction on venous hyperplasia in an experimental balloon-induced injury model

  2023cites this paper
• Update on Cilostazol: A Critical Review of Its Antithrombotic and Cardiovascular Actions and Its Clinical Applications

  2021cites this paper
• Preliminary Phytochemical Screening, In Vitro Antidiabetic, Antioxidant Activities, and Toxicity of Leaf Extracts of Psychotria malayana Jack

  2021cites this paper
• [Prospects of clinical application of cilostazol for peripheral artery disease].

  2020cites this paper
• Antiplatelet Therapy

  2020cites this paper
• Cilostazol attenuates intimal hyperplasia in a mouse model of chronic kidney disease

  2017cites this paper
• Peripheral Arterial Disease

  2016cites this paper
• The improvement in the ABI index following 3 month treatment with cilostazol in patients with mild to moderate peripheral arterial disease

  2014cites this paper
• Atherosclerotic coronary plaque regression and the risk of adverse cardiovascular events: a meta-regression of randomized clinical trials.

  2013cites this paper
• Chapter 57 – Cilostazol

  2013cites this paper
• atic Reverse Phase HPLC Method-Determination and Validation of Cilostazol

  2013cites this paper
• Isocratic Reverse Phase HPLC

  2013cites this paper
• Cilostazol and primary-PCI: mirage or good alternative?

  2012cites this paper
• Novel bismuth/multi-walled carbon nanotubes-based electrochemical sensor for the determination of neuroprotective drug cilostazol

  2012cites this paper
• Benefit, rather than safety, of cilostazol for long-term mortality in patients undergoing percutaneous coronary intervention: a meta-analysis of randomized trials.

  2011cites this paper
• Cilostazol reduces restenosis after carotid artery stenting.

  2010cites this paper
• Cilostazol suppresses neointimal hyperplasia in canine vein grafts

  2009cites this paper
• Efficacy of cilostazol in reducing restenosis in patients undergoing contemporary stent based PCI: a meta-analysis of randomised controlled trials.

  2009cites this paper
• The primary and secondary prevention of coronary artery disease: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition).

  2008cites this paper
• Systematic review and meta-analysis of randomized clinical trials appraising the impact of cilostazol after percutaneous coronary intervention.

  2008cites this paper
• Practice Guidelines (8th Edition) of Chest Physicians Evidence-Based Clinical Coronary Artery Disease: American College The Primary and Secondary Prevention of

  2008cites this paper
• metabolism of cilostazol

  2007cites this paper
• Pharmacologic approaches to restenosis prevention.

  2007cites this paper
• Characterization of Human Cytochrome P450 Enzymes Involved in the Metabolism of Cilostazol

  2007cites this paper
• The Cardioprotective Effect of a Statin and Cilostazol Combination: Relationship to Akt and Endothelial Nitric Oxide Synthase Activation

  2007cites this paper
• Cilostazol in the management of vascular disease.

  2007cites this paper
• Activation of Platelet Function Through G Protein–Coupled Receptors Platelets As Immune Cells: Bridging Inflammation and Cardiovascular Disease In Vivo Thrombus Formation in Murine Models Clinical Aspects of Platelet Inhibitors and Thrombus Formation Platelet Adhesion

  2007cites this paper
• The vascular effects of cilostazol.

  2006cites this paper
• Role of adjunct pharmacologic therapy in the era of drug-eluting stents.

  2005cites this paper
• Cilostazol reduces target lesion revascularization after percutaneous transluminal angioplasty in the femoropopliteal artery.

  2005cites this paper
• The Multiple Combined Oral Platelet Aggregation Inhibitors of Aspirin, Ticlopidine and Cilostazol after PCI

  2004cites this paper
• THE EFFECT OF CILOSTAZOL ON THE TISSUE FACTOR EXPRESSION IN HUVECs AND HUMAN MONOCYTES

  2004cites this paper
• Balloon angioplasty plus cilostazol administration versus primary stenting of small coronary artery disease: Final results of COMPASS

  2004cites this paper
• Cilostazol as a unique antithrombotic agent.

  2003cites this paper
• Debulking and stenting versus debulking only of coronary artery disease in patients treated with cilostazol (final results of ESPRIT).

  2002cites this paper
• Reevaluating the role of phosphodiesterase inhibitors in the treatment of cardiovascular disease

  2002cites this paper
• Potential emerging therapeutic strategies to prevent restenosis in the peripheral vasculature

  2002cites this paper
• The pharmacology of cilostazol

  2002cites this paper
• Correlation between serum hepatocyte growth factor level and percutaneous coronary balloon angioplasty: An alternative mechanism of reduction in restenosis with citostazol

  2001cites this paper
• Pharmacological treatment for prevention of restenosis

  2001cites this paper
• Correlation between serum hepatocyte growth factor level and percutaneous coronary balloon angioplasty: An alternative mechanism of reduction in restenosis with citostazol

  2001cites this paper
• Effects of cilostazol on late lumen loss and repeat revascularization after Palmaz-Schatz coronary stent implantation.

  2001cites this paper
• Endovascular and surgical revascularization for patients with intermittent claudication.

  2001cites this paper
• Effect of cilostazol on restenosis after coronary angioplasty and stenting in comparison to conventional coronary artery stenting with ticlopidine.

  2001cites this paper
• Cilostazol: Treatment of Intermittent Claudication

  2001cites this paper
• Regulation and function of the cyclic nucleotide phosphodiesterase (PDE3) gene family.

  2001cites this paper
• Decrease in carotid intima media thickness after 1 year of cilostazol treatment in patients with type 2 diabetes mellitus.

  2001cites this paper
• Novel approaches for the prevention of restenosis

  2000cites this paper
• Suppression of arterial intimal hyperplasia by cilostamide, a cyclic nucleotide phosphodiesterase 3 inhibitor, in a rat balloon double‐injury model

  2000cites this paper
• Nitric oxide and postangioplasty restenosis: pathological correlates and therapeutic potential.

  2000cites this paper
• Final results of the STent versus directional coronary Atherectomy Randomized Trial (START)

  1999cites this paper
• The Utility of Animal Models in the Preclinical Study of Interventions to Prevent Human Coronary Artery Restenosis: Analysis and Recommendations

  1999cites this paper
• The Anticoagulant and Antiplatelet Therapy in Cardiovascular Patients

  1999cites this paper
• Impact of cilostazol on clinical and angiographic outcome after primary stenting for acute myocardial infarction.

  1999cites this paper
• Cilostazol

  1999cites this paper
• Impact of cilostazol on restenosis after percutaneous coronary balloon angioplasty.

  1999cites this paper
• Cyclic Nucleotide Phosphodiesterases (PDEs): Diverse Regulators of Cyclic Nucleotide Signals and Inviting Molecular Targets for Novel Therapeutic Agents

  1999cites this paper
• Antiplatelet Therapy Using Cilostazol, a Specific PDE3 Inhibitor

  1999cites this paper